p. 1−5
2357-0717
Vol.20/No.1
p. 1−6
2357-0717
Vol.20/No.1
p. 1−14
2357-0717
Vol.20/No.1
p. 1−7
2357-0717
Vol.20/No.1
p. 1−8
2357-0717
Vol.20/No.1
p. 1−8
2357-0717
Vol.20/No.1
p. 1−11
2357-0717
Vol.20/No.1
p. 1−8
2357-0717
Vol.20/No.1
p. 1−6
2357-0717
Vol.20/No.1
120 Group 3 consists of 10 patients who are microalbuminuric i.e. UAE 30-300 mg/day. Group 4 consists of 10 patients who are macroalbuminuric i.e. UAE ≥ 300 mg/day without renal impairment (normal creatinine and GFR > 90 ml/min/1.73m²). Group 5 consists of 10 patients who are macroalbuminuric with renal impairment and declining GFR <90 ml/min/1.73m². Group 6 consists of 10 patients who are end-stage renal disease (GFR <15 ml/min/1.73m²). Measurement of serum AFABP4 , serum RBP4 , UAE, GFR were done for every subjectResults: There was significant increase in the serum level of AFABP4 and RBP4 among different stages of diabetic nephropathy and there was significant difference between microalbuminuric group and normoalbuminuric group so both biomarkers can be used for early detection of diabetic nephropathy. Both AFABP4 and RBP4 correlated positively with UAE and negatively with GFR. Conclusion: High circulating AFABP4 and RBP4 concentrations were demonstrated in early diabetic nephropathy in type 2 DM. AFABP4 and RBP4 increased significantly with the progression of diabetic nephropathy. Large scale multicenter and prospective studies are necessary to gather a definitive support that these adipokines might be directly involved in early detection of diabetic nephropathy and in impairment of kidney function in type 2 DM.]]>
p. 1−12
2357-0717
Vol.20/No.1
p. 1−9
2357-0717
Vol.20/No.1
p. 1−8
2357-0717
Vol.20/No.1
p. 1−7
2357-0717
Vol.20/No.1
p. 1−7
2357-0717
Vol.20/No.1
p. 1−9
2357-0717
Vol.20/No.1
p. 1−7
2357-0717
Vol.20/No.1